% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gschel:274036,
      author       = {Göschel, Laura and Dell Orco, Andrea and Fillmer, Ariane
                      and Aydin, Semiha and Ittermann, Bernd and Riemann, Layla
                      and Lehmann, Sylvain and Cano, Stefan and Melin, Jeanette
                      and Pendrill, Leslie and Hoede, Patty L and Teunissen,
                      Charlotte E and Schwarz, Claudia and Grittner, Ulrike and
                      Körtvelyessy, Peter and Flöel, Agnes},
      title        = {{P}lasma p-tau181 and {GFAP} reflect 7{T} {MR}-derived
                      changes in {A}lzheimer's disease: {A} longitudinal study of
                      structural and functional {MRI} and {MRS}.},
      journal      = {Alzheimer's and dementia},
      volume       = {20},
      number       = {12},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-00017},
      pages        = {8684 - 8699},
      year         = {2024},
      abstract     = {Associations between longitudinal changes of plasma
                      biomarkers and cerebral magnetic resonance (MR)-derived
                      measurements in Alzheimer's disease (AD) remain unclear.In a
                      study population (n = 127) of healthy older adults and
                      patients within the AD continuum, we examined associations
                      between longitudinal plasma amyloid beta 42/40 ratio, tau
                      phosphorylated at threonine 181 (p-tau181), glial fibrillary
                      acidic protein (GFAP), neurofilament light chain (NfL), and
                      7T structural and functional MR imaging and spectroscopy
                      using linear mixed models.Increases in both p-tau181 and
                      GFAP showed the strongest associations to 7T MR-derived
                      measurements, particularly with decreasing parietal cortical
                      thickness, decreasing connectivity of the salience network,
                      and increasing neuroinflammation as determined by MR
                      spectroscopy (MRS) myo-inositol.Both plasma p-tau181 and
                      GFAP appear to reflect disease progression, as indicated by
                      7T MR-derived brain changes which are not limited to areas
                      known to be affected by tau pathology and neuroinflammation
                      measured by MRS myo-inositol, respectively.This study
                      leverages high-resolution 7T magnetic resonance (MR) imaging
                      and MR spectroscopy (MRS) for Alzheimer's disease (AD)
                      plasma biomarker insights. Tau phosphorylated at threonine
                      181 (p-tau181) and glial fibrillary acidic protein (GFAP)
                      showed the largest changes over time, particularly in the AD
                      group. p-tau181 and GFAP are robust in reflecting 7T
                      MR-based changes in AD. The strongest associations were for
                      frontal/parietal MR changes and MRS neuroinflammation.},
      keywords     = {Humans / Alzheimer Disease: blood / Alzheimer Disease:
                      pathology / Alzheimer Disease: diagnostic imaging / tau
                      Proteins: blood / Female / Longitudinal Studies / Male /
                      Aged / Magnetic Resonance Imaging / Glial Fibrillary Acidic
                      Protein: blood / Biomarkers: blood / Magnetic Resonance
                      Spectroscopy / Brain: diagnostic imaging / Brain: pathology
                      / Amyloid beta-Peptides: blood / Phosphorylation / Disease
                      Progression / Middle Aged / Neurofilament Proteins: blood /
                      7 Tesla (Other) / Alzheimer's disease (Other) / NeuroMET
                      Memory Metric (Other) / amyloid beta 42/40 (Other) /
                      blood‐based biomarkers (Other) / functional magnetic
                      resonance imaging (Other) / glial fibrillary acidic protein
                      (Other) / magnetic resonance imaging (Other) / magnetic
                      resonance spectroscopy (Other) / memory (Other) / mild
                      cognitive impairment (Other) / neurofilament light chain
                      (Other) / plasma biomarkers (Other) / subjective cognitive
                      decline (Other) / tau phosphorylated at threonine 181
                      (Other) / tau Proteins (NLM Chemicals) / Glial Fibrillary
                      Acidic Protein (NLM Chemicals) / Biomarkers (NLM Chemicals)
                      / Amyloid beta-Peptides (NLM Chemicals) / GFAP protein,
                      human (NLM Chemicals) / Neurofilament Proteins (NLM
                      Chemicals)},
      cin          = {AG Flöel / AG Düzel},
      ddc          = {610},
      cid          = {I:(DE-2719)5000081 / I:(DE-2719)5000006},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39558898},
      pmc          = {pmc:PMC11667506},
      doi          = {10.1002/alz.14318},
      url          = {https://pub.dzne.de/record/274036},
}